Expression of gemcitabine-and cisplatin-related genes in non-small-cell lung cancer

F. Toffalorio, E. Giovannetti, T. De Pas, D. Radice, G. Pelosi, M. Manzotti, D. Minocci, L. Spaggiari, G. Spitaleri, C. Noberasco, C. Catania, S. Boselli, R. Danesi, F. De Braud

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The aim of this study was to investigate the influence of histology and site of analysis (primary tumor versus lymph node) on the expression of genes involved in gemcitabine and cisplatin activity in non-small-cell lung cancer (NSCLC). Excision repair cross-complementing-1 (ERCC1), human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (dCK), 5′-nucleotidase (5′-NT), cytidine deaminase (CDA) and ribonucleotide-reductase regulatory subunits (RRM1 and RRM2) were analyzed by quantitative-reverse transcription-PCR in 88 microdissected samples from 69 chemonaive patients. The results showed different patterns of expression for all studied genes, suggesting a possible stratification of the patients. No difference was observed between primary tumor and lymph node metastasis, as well as in adenocarcinoma and squamous-cell carcinoma specimens, while we found a correlation between the CDA-A79C polymorphism and gene expression levels. These data suggest a similar genetic susceptibility to gemcitabine-cisplatin regimens for squamous cell and adenocarcinoma and support the use of both lymph node and primary tumor for the expression profiling of NSCLC.

Original languageEnglish
Pages (from-to)180-190
Number of pages11
JournalPharmacogenomics Journal
Volume10
Issue number3
DOIs
Publication statusPublished - Jun 2010

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
Cytidine Deaminase
Cisplatin
Lymph Nodes
Adenocarcinoma
Deoxycytidine Kinase
Genes
Ribonucleotide Reductases
Gene Expression
Neoplasms
5'-Nucleotidase
Genetic Predisposition to Disease
DNA Repair
Reverse Transcription
Squamous Cell Carcinoma
Histology
Epithelial Cells
Neoplasm Metastasis
Polymerase Chain Reaction

Keywords

  • Cisplatin
  • Gemcitabine
  • Gene expression
  • Histotype
  • NSCLC
  • Stage

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Expression of gemcitabine-and cisplatin-related genes in non-small-cell lung cancer. / Toffalorio, F.; Giovannetti, E.; De Pas, T.; Radice, D.; Pelosi, G.; Manzotti, M.; Minocci, D.; Spaggiari, L.; Spitaleri, G.; Noberasco, C.; Catania, C.; Boselli, S.; Danesi, R.; De Braud, F.

In: Pharmacogenomics Journal, Vol. 10, No. 3, 06.2010, p. 180-190.

Research output: Contribution to journalArticle

@article{0f72cbff0933415ea56c3cb44804c6c4,
title = "Expression of gemcitabine-and cisplatin-related genes in non-small-cell lung cancer",
abstract = "The aim of this study was to investigate the influence of histology and site of analysis (primary tumor versus lymph node) on the expression of genes involved in gemcitabine and cisplatin activity in non-small-cell lung cancer (NSCLC). Excision repair cross-complementing-1 (ERCC1), human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (dCK), 5′-nucleotidase (5′-NT), cytidine deaminase (CDA) and ribonucleotide-reductase regulatory subunits (RRM1 and RRM2) were analyzed by quantitative-reverse transcription-PCR in 88 microdissected samples from 69 chemonaive patients. The results showed different patterns of expression for all studied genes, suggesting a possible stratification of the patients. No difference was observed between primary tumor and lymph node metastasis, as well as in adenocarcinoma and squamous-cell carcinoma specimens, while we found a correlation between the CDA-A79C polymorphism and gene expression levels. These data suggest a similar genetic susceptibility to gemcitabine-cisplatin regimens for squamous cell and adenocarcinoma and support the use of both lymph node and primary tumor for the expression profiling of NSCLC.",
keywords = "Cisplatin, Gemcitabine, Gene expression, Histotype, NSCLC, Stage",
author = "F. Toffalorio and E. Giovannetti and {De Pas}, T. and D. Radice and G. Pelosi and M. Manzotti and D. Minocci and L. Spaggiari and G. Spitaleri and C. Noberasco and C. Catania and S. Boselli and R. Danesi and {De Braud}, F.",
year = "2010",
month = "6",
doi = "10.1038/tpj.2009.53",
language = "English",
volume = "10",
pages = "180--190",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Expression of gemcitabine-and cisplatin-related genes in non-small-cell lung cancer

AU - Toffalorio, F.

AU - Giovannetti, E.

AU - De Pas, T.

AU - Radice, D.

AU - Pelosi, G.

AU - Manzotti, M.

AU - Minocci, D.

AU - Spaggiari, L.

AU - Spitaleri, G.

AU - Noberasco, C.

AU - Catania, C.

AU - Boselli, S.

AU - Danesi, R.

AU - De Braud, F.

PY - 2010/6

Y1 - 2010/6

N2 - The aim of this study was to investigate the influence of histology and site of analysis (primary tumor versus lymph node) on the expression of genes involved in gemcitabine and cisplatin activity in non-small-cell lung cancer (NSCLC). Excision repair cross-complementing-1 (ERCC1), human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (dCK), 5′-nucleotidase (5′-NT), cytidine deaminase (CDA) and ribonucleotide-reductase regulatory subunits (RRM1 and RRM2) were analyzed by quantitative-reverse transcription-PCR in 88 microdissected samples from 69 chemonaive patients. The results showed different patterns of expression for all studied genes, suggesting a possible stratification of the patients. No difference was observed between primary tumor and lymph node metastasis, as well as in adenocarcinoma and squamous-cell carcinoma specimens, while we found a correlation between the CDA-A79C polymorphism and gene expression levels. These data suggest a similar genetic susceptibility to gemcitabine-cisplatin regimens for squamous cell and adenocarcinoma and support the use of both lymph node and primary tumor for the expression profiling of NSCLC.

AB - The aim of this study was to investigate the influence of histology and site of analysis (primary tumor versus lymph node) on the expression of genes involved in gemcitabine and cisplatin activity in non-small-cell lung cancer (NSCLC). Excision repair cross-complementing-1 (ERCC1), human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (dCK), 5′-nucleotidase (5′-NT), cytidine deaminase (CDA) and ribonucleotide-reductase regulatory subunits (RRM1 and RRM2) were analyzed by quantitative-reverse transcription-PCR in 88 microdissected samples from 69 chemonaive patients. The results showed different patterns of expression for all studied genes, suggesting a possible stratification of the patients. No difference was observed between primary tumor and lymph node metastasis, as well as in adenocarcinoma and squamous-cell carcinoma specimens, while we found a correlation between the CDA-A79C polymorphism and gene expression levels. These data suggest a similar genetic susceptibility to gemcitabine-cisplatin regimens for squamous cell and adenocarcinoma and support the use of both lymph node and primary tumor for the expression profiling of NSCLC.

KW - Cisplatin

KW - Gemcitabine

KW - Gene expression

KW - Histotype

KW - NSCLC

KW - Stage

UR - http://www.scopus.com/inward/record.url?scp=77952886846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952886846&partnerID=8YFLogxK

U2 - 10.1038/tpj.2009.53

DO - 10.1038/tpj.2009.53

M3 - Article

C2 - 19901957

AN - SCOPUS:77952886846

VL - 10

SP - 180

EP - 190

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 3

ER -